Viatris Inc.
18.00USD
-0.4800 (-2.60%)
Computing valuation metrics…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on VTRS.
Valuation
P/E (TTM)
—
P/E (Forward)
6.67x
EV/EBITDA
12.07x
EV/Revenue
2.23x
P/S (TTM)
1.41x
P/B
1.45x
FCF Yield
9.46%
Dividend Yield
2.67%
Gross Margin
34.93%
Operating Margin
-0.59%
Net Margin
-4.56%
Peer Comparison — Drug Manufacturers - Specialty & Generic
| Company | Mkt Cap | P/E | EV/EBITDA | FCF Yield | Rev Growth | Div Yield |
|---|---|---|---|---|---|---|
| VTRSViatris Inc. | $20.67B | — | 12.07x | 9.46% | 4.96% | 2.67% |
| TEVATeva Pharmaceutical Industries Limited | $45.96B | 65.68x | 13.86x | 4.83% | -0.80% | 0.00% |
Subject metrics from SEC filings where available; peer metrics from cached market data.
| $33.48B |
| 13.33x |
| 10.10x |
| 6.02% |
| -0.20% |
| 2.62% |
| UTHRUnited Therapeutics Corporation | $25.20B | 21.04x | 15.06x | 2.21% | -1.90% | 0.00% |
| HIMSHims & Hers Health, Inc. | $6.47B | — | — | 13.14% | 38.20% | 0.00% |
| KNSAKiniksa Pharmaceuticals International, plc | $5.90B | 77.51x | 53.60x | 2.14% | 55.40% | 0.00% |
| LQDALiquidia Corporation | $3.82B | 30.68x | 21.89x | 1.95% | 1842.70% | 0.00% |
| RGCRegencell Bioscience Holdings Limited | $3.80B | — | — | -0.08% | — | 0.00% |
| AMLXAmylyx Pharmaceuticals, Inc. | $3.41B | — | — | -2.26% | — | 0.00% |